Park, C.-W. (2020) “The safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis”, EXCLI Journal, 19, pp. 187–200. doi: 10.17179/excli2019-2058.